CD10 expression in gastric carcinoma is correlated with tumor grade and survival

Main Article Content

Amir Hosein Jafarian
Melika Kooshki Forooshani
Leila Takallou
Nema Mohamadian Roshan


Gastric carcinoma (GC) is the most common non-skin malignancy in Iranian men and the second leading cause of cancer-related mortality. Invasion and metastasis are considered as the major causes of cancer-related morbidity and mortality. Proteinases such as matrix metalloproteinases play an important role in tumor progression and mediating extracellular matrix remodeling. CD10 is a 90-110kd cell surface zinc-dependent metalloproteinase and there is evidence that this membrane protein may facilitate invasion and/or metastasis of tumoral cells. The objective of this study was to determine the frequency of CD10 expression in the stromal cells of GC and determine its relationship with survival and clinicopathological factors.

A cross-sectional study was performed involving 50 patients with histopathologic diagnosis of GC. CD10 expression was determined by immunohistochemistry (IHC). Survival of the patients as well as the grade and stage of the tumors and demographic variables were documented. The Kaplan-Meier test was used for data analysis.

Stromal CD10 was detected in 46% of the GC stromal cells. No immunoreactivity was identified in the stromal cells of normal adjacent tissue. Stromal CD10 expression in gastric carcinoma did not correlate with the age and gender of the cases as well as the size and location of the tumor, and lymph node involvement but correlated with tumor stage (p=0.01), tumor grade(p=0.01) and patients’ survival (p=0.02).

Stromal CD10 expression is correlated with tumor differentiation, clinical stage and survival in GC. CD10 expression could be considered as a negative prognostic factor for gastric carcinoma.

Article Details

How to Cite
Jafarian, A. H., Kooshki Forooshani, M., Takallou, L., & Mohamadian Roshan, N. (2019). CD10 expression in gastric carcinoma is correlated with tumor grade and survival. Universa Medicina, 38(1), 41–47.
Original Articles


Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-13. doi: 10.1158/1055-9965.EPI-13-1057.

Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917. doi: 10.1002/ijc.25516.

Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet 2016; 388: 2654-64. doi: 10.1016/S0140-6736(16)30354-3.

Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380: 1840–50. doi: 10.1016/S0140-6736(12)60919-2.

Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells 2011;29:389–96. doi: 10.1002/stem.592.

Oba J, Nakahara T, Hashimoto-Hachiya A, et al. CD10-equipped melanoma cells acquire highly potent tumorigenic activity: a plausible explanation of their significance for a poor prognosis. PLoS One 2016;11:e0149285. doi: 10.1371/journal.pone.0149285.

Fukusumi T, Ishii H, Konno M, et al. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma. Br J Cancer 2014;111:506-14. doi: 10.1038/bjc.2014.289.

Salibay CJ, Rewerska J, Gupta S, et al Primary carcinosarcoma of the pancreas with CD10-positive sarcoma component. J Investig Med High Impact Case Rep 2017;5:2324709617740906. doi: 10.1177/2324709617740906.

Murakami T, Yao T, Mitomi H, et al. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation. Gastric Cancer 2016;19:498-507. doi: 10.1007/s10120-015-0497-9.

Ohnishi N, Takata K, Miyata-Takata T, et al. CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine. Cancer Sci. 2016;107:1687-95. doi: 10.1111/cas.13031.

Huang WB, Zhou XJ, Chen JY, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol 2005;35:245–50. doi:10.1093/jjco/hyi076.

Feng F, Liu J, Wang F, et al. Prognostic value of differentiation status in gastric cancer. BMC Cancer 2018;18:865. doi: 10.1186/s12885-018-4780-0.

Giampieri R, Del Prete M, Cantini L, et al. Optimal management of resected gastric cancer. Cancer Manag Res 2018;10:1605–18. doi: 10.2147/CMAR.S151552.

Zhang J, Gan L, Xu MD, et al. The prognostic value of age in non-metastatic gastric cancer after gastrectomy: a retrospective study in the U.S. and China. J Cancer 2018;9:1188–99. doi: 10.7150/jca.22085.

Xu J, Medeiros LJ, Saksena A, et al. CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. Oncotarget 2018;9:11441-50. doi: 10.18632/oncotarget.23571.

Kadota K, Buitrago D, Lee MC, et al. Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. Lung Cancer 2015;89:329-36. doi: 10.1016/j.lungcan.2015.06.003.

Zhu Y, Zheng JJ, Yang F, et al. Expression of CD10 in cancer-associated fibroblasts and its effect on initiation and progression of colorectal carcinoma. Chin J Pathol 2016;45:859-65. doi: 10.3760/cma.j.issn.0529-5807.2016.12.009.

Taghizadeh-Kermani A, Jafarian AH, Ashabyamin R, et al. The stromal overexpression of CD10 in invasive breast cancer and its association with clincophathologic factors. Iran J Cancer Prev 2014;7:17-21.

Puri V, Jain M, Thomas S. Stromal expression of CD10 in invasive breast carcinoma and its correlation with ER, PR, HER2-neu, and Ki67. Int J Breast Cancer 2011, Article ID 437957, 4 pages. DOI:

Kaur M, Verma S, Gupta R, et al. CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason’s grades. Malays J Pathol 2018 40:57-60.

Kim DH, Shin N, Kim GH, et al. Mucin expression in gastric cancer: reappraisal of its clinicopathologic and prognostic significance. Arch Pathol Lab Med 2013;137:1047–53. doi: 10.5858/arpa.2012-0193-OA.